Gt biopharma presents two posters at the society for immunotherapy of cancer's (sitc) 37th annual meeting

Brisbane, california, nov. 10, 2022 (globe newswire) -- gt biopharma, inc. (the “company” or “gtb”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, will present two poster presentations at the society for immunotherapy of cancer's 37th annual meeting (sitc 2022), to be held in boston, massachusetts and virtually on november 8-12, 2022. the two posters highlight tri-specific killer engagers for the treatment of mesothelioma and prostate cancer.
GTBP Ratings Summary
GTBP Quant Ranking